95
6. Türk
Tıbbi
Onkoloji
Kongresi
Torasik Onkoloji
zed phase II trial of gemcitabine-cisplatin with or without trastu-
zumab in HER2-positive non-small-cell lung cancer. Ann. Oncol.
2004, 15, 19–27.
23. Zinner, R.G.; Glisson, B.S.; Fossella, F.V.; Pisters, K.M.W.; Kies,
M.S.; Lee, P.M.; Massarelli, E.; Sabloff, B.; Fritsche, H.A.; Ro, j.Y.;
et al. Trastuzumab in combination with cisplatin and gemcitabi-
ne in patients with Her2-overexpressing, untreated, advanced
non-small cell lung cancer: Report of a phase II trial and findings
regarding optimal identification of patients with Her2-overexp-
ressing d. Lung Cancer 2004, 44, 99–110.
24. Ross, H.j.; Blumenschein, G.R.; Aisner, j.; Damjanov, N.; Dow-
lati, A.; Garst, j.; Rigas, j.R.; Smylie, M.; Hassani, H.; Allen, K.E.;
et al. Randomized phase II multicenter trial of two schedules of
lapatinib as first- or second-line monotherapy in patients with
advanced or metastatic non-small cell lung cancer. Clin. Cancer
Res. 2010, 16, 1938–1949.
25. Mazières, j.; Peters, S.; Lepage, B.; Cortot, A.B.; Barlesi, F.; Be-
au-Faller, M.; Besse, B.; Blons, H.; Mansuet-Lupo, A.; Urban, T.;
et al. Lung cancer that harbors an HER2 mutation: Epidemiologic
characteristics and therapeutic perspectives. j. Clin. Oncol. 2013,
31, 1997–2003.
26. Onozato, R.; Kosaka, T.; Kuwano, H.; Sekido, Y.; Yatabe, Y.; Mitsu-
domi, T. Activation of MET by gene amplification or by splice mu-
tations deleting the juxtamembrane domain in primary resected
lung cancers. j. Thorac. Oncol. 2009, 4, 5–11.
27. Beau-Faller, M.; Ruppert, A.-M.; Voegeli, A.-C.; Neuville, A.;
Meyer, N.; Guerin, E.; Legrain, M.; Mennecier, B.; Wihlm, j.-M.;
Massard, G.; et al. MET gene copy number in non-small cell lung
cancer: Molecular analysis in a targeted tyrosine kinase inhibitor
naïve cohort. j. Thorac. Oncol. 2008, 3, 331–339.
28. Tsao, M.S.; Liu, N.; Chen, j.R.; Pappas, j.; Ho, j.; To, C.; Viallet,
j.; Park, M.; Zhu, H. Differential expression of Met/hepatocyte
growth factor receptor in subtypes of non-small cell lung can-
cers. Lung Cancer 1998, 20, 1–16.
29. Spigel, D.R.; Edelman, M.j.; O’Byrne, K.; Paz-Ares, L.; Shames,
D.S.; Yu, W.; Paton, V.E.; Mok, T.; Sarah Cannon Research Insti-
tute; Nashville, T.N.; et al. Onartuzumab plus erlotinib versus er-
lotinib in previously treated stage IIIb or IV NSCLC: Results from
the pivotal phase III randomized, multicenter, placebo-controlled
METLung (OAM4971g) global trial. j. Clin. Oncol. 2014, 32, 8000.
30. Patnaik, A.; Weiss, G.j.; Papadopoulos, K.P.; Hofmeister, C.C.; Ti-
bes, R.; Tolcher, A.; Isaacs, R.; jac, j.; Han, M.; Payumo, F.C.; et
al. Phase I ficlatuzumab monotherapy or with erlotinib for refrac-
tory advanced solid tumours and multiple myeloma. Br. j. Cancer
2014, 111, 272–280.
31. Gordon, M.S.; Sweeney, C.S.; Mendelson, D.S.; Eckhardt, S.G.;
Anderson, A.; Beaupre, D.M.; Branstetter, D.; Burgess, T.L.;
Coxon, A.; Deng, H.; et al. Safety, pharmacokinetics, and phar-
macodynamics of AMG 102, a fully human hepatocyte growth fa-
ctor-neutralizing monoclonal antibody, in a first-in-human study
of patients with advanced solid tumors. Clin. Cancer Res. 2010,
16, 699–710.
32. Sequist, L.V.; von Pawel, j.; Garmey, E.G.; Akerley, W.L.; Brug-
ger, W.; Ferrari, D.; Chen, Y.; Costa, D.B.; Gerber, D.E.; Orlov, S.; et
al. Randomized phase II study of erlotinib plus tivantinib versus
erlotinib plus placebo in previously treated non-small-cell lung
cancer. j. Clin. Oncol. 2011, 29, 3307–3315.
33. Ou, S.H.; Kwak, E.L.; Siwak-Tapp, C.; Dy, j.; Bergethon, K.; Clark,
j.W.; Camidge, D.R.; Solomon, B.j.; Maki, R.G.; Bang, Y.j.; et al.
Activity of crizotinib (PF02341066), a dual mesenchymal-epithe-
lial transition (MET) and anaplastic lymphoma kinase (ALK) in-
hibitor, in a non-small cell lung cancer patient with de novo MET
amplification. j. Thorac. Oncol. 2011, 6, 942–946.
34. Wang, R.; Hu, H.; Pan, Y.; Li, Y.; Ye, T.; Li, C.; Luo, X.; Wang, L.; Li,
H.; Zhang, Y.; et al. RET fusions define a unique molecular and
clinicopathologic subtype of non-small-cell lung cancer. j. Clin.
Oncol. 2012, 30, 4352–4359.
35. Kodama, T.; Tsukaguchi, T.; Satoh, Y.; Yoshida, M.; Watanabe,
Y.; Kondoh, O.; Sakamoto, H. Alectinib shows potent antitumor
activity against RET-rearranged non-small cell lung cancer. Mol.
Cancer Ther. 2014, 13, 2910–2918.
36. Kawano, O.; Sasaki, H.; Okuda, K.; Yukiue, H.; Yokoyama, T.; Yano,
M.; Fujii, Y. PIK3CA gene amplification in japanese non-small cell
lung cancer. Lung Cancer 2007, 58, 159–160.
37. The Cancer Genome Atlas Research Network. Comprehensive
genomic characterization of squamous cell lung cancers. Nature
2012, 489, 519–525.
38. Chaft, j.E.; Arcila, M.E.; Paik, P.K.; Lau, C.; Riely, G.j.; Pietanza,
M.C.; Zakowski, M.F.; Rusch, V.; Sima, C.S.; Ladanyi, M.; et al.
Coexistence of PIK3CA and other oncogene mutations in lung
adenocarcinoma-rationale for comprehensive mutation profiling.
Mol. Cancer Ther. 2012, 11, 485–491.
39. Dutt, A.; Ramos, A.H.; Hammerman, P.S.; Mermel, C.; Cho, j.;
Sharifnia, T.; Chande, A.; Tanaka, K.E.; Stransky, N.; Greulich,
H.; et al. Inhibitor-sensitive FGFR1 amplification in human non-
small cell lung cancer. PLoS ONE 2011, 6, e20351.
40. Liao, R.G.; jung, j.; Tchaicha, j.; Wilkerson, M.D.; Sivachenko,
A.; Beauchamp, E.M.; Liu, Q.; Pugh, T.j.; Pedamallu, C.S.; Hayes,
D.N.; et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in
lung squamous cell carcinoma. Cancer Res. 2013, 73, 5195–5205.
41. Vogel, W. Discoidin domain receptors: structural relations and
functional implications. FASEB j. 1999, 13, S77–S82.
42. Hammerman, P.S.; Sos, M.L.; Ramos, A.H.; Xu, C.; Dutt, A.; Zhou,
W.; Brace, L.E.; Woods, B.A.; Lin, W.; Zhang, j.; et al. Mutations in
the DDR2 kinase gene identify a novel therapeutic target in squa-
mous cell lung cancer. Cancer Discov. 2011, 1, 78–89.
43. Marks, j.L.; Gong, Y.; Chitale, D.; Golas, B.; McLellan, M.D.; Kasai,
Y.; Ding, L.; Mardis, E.R.; Wilson, R.K.; Solit, D.; et al. Novel MEK1
mutation identified by mutational analysis of epidermal growth
factor receptor signaling pathway genes in lung adenocarcinoma.
Cancer Res. 2008, 68, 5524–5528.
44. . De Braud, F.G.; Pilla, L.; Niger, M.; Damian, S.; Bardazza, B.;
Martinetti, A.; Pelosi, G.; Marrapese, G.; Palmeri, L.; Cerea, G.;
et al. Phase 1 open label, dose escalation study of RXDX101, an
oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced
solid tumors with relevant molecular alterations. j. Clin. Oncol.
2014, 32, 2502.
45. jin, G.; Kim, M.j.; jeon, H.-S.; Choi, j.E.; Kim, D.S.; Lee, E.B.; Cha,
S.I.; Yoon, G.S.; Kim, C.H.; jung, T.H.; et al. PTEN mutations and
relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-
small cell lung cancers. Lung Cancer 2010, 69, 279–283.
46. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and
histological evolution of lung cancers acquiring resistance to
EGFR inhibitors. Sci Transl Med 2011; 3:75ra26.
47. National Comprehensive Cancer Network. NCCN Clinical Practice
Guidelines in Oncology: Non-Small Cell Lung Cancer; NCCN: Fort
Washington, PA, USA, 2015.
48. Lopez-Chavez, A.; Thomas, A.; Rajan, A.; Raffeld, M.; Morrow, B.;
Kelly, R.; Carter, C.A.; Guha, U.; Killian, K.; Lau, C.C.; et al. Mole-
cular profiling and targeted therapy for advanced thoracic malig-
nancies: A Biomarker-derived, multiarm, multihistology phase II
basket trial. j. Clin. Oncol. 2015, 33, 1000–1007.